Cizzle Biotechnology (LSE:CIZ) has reported further progress toward the U.S. rollout of its CIZ1B blood test designed for early detection of lung cancer, as its North American partner, Cizzle Bio Inc., moves closer to completing validation work with Omni Health Diagnostics in Texas. The programme is advancing toward a planned application for CLIA accreditation expected in the second quarter of 2026.
The companies have also updated their financial agreement, confirming that Cizzle Biotechnology will receive the remaining US$1.81 million of initial advance royalty payments by the end of 2026. In addition, the revised terms include a guaranteed minimum of US$3.5 million in royalty income beginning in 2031, bringing total contracted revenue linked to the partnership to at least US$5.9 million and providing longer-term financial visibility as the test is introduced across North America.
Despite operational progress, the company’s outlook remains constrained by weak financial fundamentals, including its pre-revenue status, continuing losses, ongoing cash consumption and a significantly reduced equity base. Technical indicators also suggest limited market momentum, while valuation support remains minimal due to negative earnings and the absence of dividend payments.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer focused on early cancer detection technologies. Its lead product is a non-invasive blood test built around the CIZ1B biomarker, which is strongly associated with early-stage lung cancer. The company primarily commercialises its technology through licensing agreements and royalty-based collaborations with partners and cancer care providers.
Leave a Reply